MX2020013557A - Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. - Google Patents
Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.Info
- Publication number
- MX2020013557A MX2020013557A MX2020013557A MX2020013557A MX2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A MX 2020013557 A MX2020013557 A MX 2020013557A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disubstituted
- pyrazolyl steroid
- subject
- compound
- Prior art date
Links
- 201000009916 Postpartum depression Diseases 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US201962841645P | 2019-05-01 | 2019-05-01 | |
| PCT/US2019/036848 WO2019241442A1 (en) | 2018-06-12 | 2019-06-12 | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013557A true MX2020013557A (es) | 2021-05-27 |
Family
ID=67211854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013557A MX2020013557A (es) | 2018-06-12 | 2019-06-12 | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. |
| MX2025000166A MX2025000166A (es) | 2018-06-12 | 2020-12-11 | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025000166A MX2025000166A (es) | 2018-06-12 | 2020-12-11 | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20210338692A1 (enExample) |
| EP (1) | EP3806863A1 (enExample) |
| JP (3) | JP2021527092A (enExample) |
| KR (1) | KR20210021005A (enExample) |
| CN (2) | CN117959309A (enExample) |
| AU (2) | AU2019287491B2 (enExample) |
| CA (1) | CA3103421A1 (enExample) |
| IL (1) | IL279315A (enExample) |
| MA (1) | MA52894A (enExample) |
| MX (2) | MX2020013557A (enExample) |
| SG (1) | SG11202012344RA (enExample) |
| TW (1) | TWI923545B (enExample) |
| WO (1) | WO2019241442A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US20230018765A1 (en) * | 2019-12-05 | 2023-01-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| CA3187178A1 (en) * | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2022165017A1 (en) * | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| JP2024510436A (ja) * | 2021-03-17 | 2024-03-07 | セージ セラピューティクス， インコーポレイテッド | 大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド |
| MX2023012728A (es) * | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. |
| MX2023012727A (es) * | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. |
| JP2025508406A (ja) * | 2022-02-16 | 2025-03-26 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ関連障害を処置するための神経活性ステロイド |
| WO2025175214A1 (en) * | 2024-02-16 | 2025-08-21 | Engrail Therapeutics, Inc. | Methods of treating generalized anxiety disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100509T1 (it) * | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US20170233433A1 (en) * | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| PH12018501923B1 (en) * | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| TW202604538A (zh) * | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
-
2019
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en not_active Ceased
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491B2/en active Active
- 2019-06-12 TW TW108120367A patent/TWI923545B/zh active
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
- 2020-12-11 MX MX2025000166A patent/MX2025000166A/es unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en not_active Abandoned
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
-
2024
- 2024-12-12 US US18/978,431 patent/US20250339447A1/en active Pending
-
2025
- 2025-04-10 JP JP2025064902A patent/JP2025108553A/ja active Pending
- 2025-08-15 AU AU2025217363A patent/AU2025217363A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200113917A1 (en) | 2020-04-16 |
| AU2019287491B2 (en) | 2025-05-15 |
| CN112533611A (zh) | 2021-03-19 |
| US20210338692A1 (en) | 2021-11-04 |
| JP2025108553A (ja) | 2025-07-23 |
| TW202005653A (zh) | 2020-02-01 |
| SG11202012344RA (en) | 2021-01-28 |
| US20220323462A1 (en) | 2022-10-13 |
| EP3806863A1 (en) | 2021-04-21 |
| JP2021527092A (ja) | 2021-10-11 |
| MA52894A (fr) | 2021-04-21 |
| AU2025217363A1 (en) | 2025-09-04 |
| CA3103421A1 (en) | 2019-12-19 |
| US20250339447A1 (en) | 2025-11-06 |
| MX2025000166A (es) | 2025-03-07 |
| TWI923545B (zh) | 2026-05-01 |
| CN117959309A (zh) | 2024-05-03 |
| KR20210021005A (ko) | 2021-02-24 |
| JP2024028849A (ja) | 2024-03-05 |
| AU2019287491A1 (en) | 2021-01-07 |
| WO2019241442A1 (en) | 2019-12-19 |
| IL279315A (en) | 2021-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| MX2023010063A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| MX2023012727A (es) | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. | |
| MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| WO2019200314A3 (en) | Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof | |
| MX2019008999A (es) | Composicion inyectable para prevenir la perdida del pelo o estimular el crecimiento del pelo. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| SG10201810404XA (en) | Combination comprising a glucocorticoid and edo-s101 | |
| PH12021550965A1 (en) | Combination therapy for treatment of hematological diseases | |
| PH12022551468A1 (en) | Compounds active towards nuclear receptors | |
| MX2021010989A (es) | Formulacion que incluye una combinacion de la hormona beta-endorfina y adrenocorticotropica. | |
| MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
| MX2021006933A (es) | Administración de sulcardina para el tratamiento de fibrilación auricular aguda. | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. |